Statement: There 55 more Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) in cohort 2 of the primary trial than in cohort 1.
Primary_evidence: Outcome Measurement:    Percentage of Participants With Best Tumor Response of Partial Response (PR) or Complete Response (CR) While On-study   CR=Disappearance of all clinical and radiologic evidence of target lesions; PR=At least 30% reduction in the sum of the longest diameter of all target lesions.   Time frame: Baseline visit and then every 8 weeks to 12 months, then every 3 months until disease progression Results 1:    Arm/Group Title: Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg   Arm/Group Description: Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered after ixabepilone as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 46   Measure Type: Number   Unit of Measure: Percentage of participants  47.8        (32.9 to 63.1) Results 2:    Arm/Group Title: Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg   Arm/Group Description: Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity After Cycle 4, dose reduction to 32 mg/m^2 implemented for all subsequent cycles. Bevacizumab, 15 mg/kg, administered after ixabepilone as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.   Overall Number of Participants Analyzed: 45   Measure Type: Number   Unit of Measure: Percentage of participants  71.1        (55.7 to 83.6)